Introduction: Nasopharyngeal carcinoma (NPC) is a lymphoepithelial malignancy of the nasopharynx, one of the etiologies is the infection of Epstein-Barr virus in undifferentiated type of nasopharyngeal carcinoma. The Epstein-Barr virus Nucleus Antigen-1 (EBNA-1) is Epstein-Barr virus-encoded proteins as regulatory virus transcription. Epithelial Growth Factor Receptor (EGFR) consist of a single polypeptide chain of amino acid, ErbB members, tyrosine kinase receptor, a transmembrane glycoprotein encoded by gen location in the short arms of a chromosome and overexpression in epithelial tumors. EGFR plays a central role in signal transduction pathways which regulate key cellular functions in epithelial malignancies. and may also present in NPC. Objective: To investigate this relation of expression patterns of EBNA-1 and EGFR in a histological type of undifferentiated nasopharyngeal carcinoma. Method: Observational, analytical study with a cross-sectional method of 34 formalin-fixed within inclusion criteria are EBNA-1 and positive staining of EGFR expression (30 patients) and exclusion criteria of negative staining of EGFR (4 patients). All biopsy samples work with paraffin embedded and resulted in hematoxylineosin undifferentiated histological types of the advanced stage in nasopharyngeal carcinoma. EBNA-1 and EGFR expression used immunohistochemistry staining. Result: EBNA-1 and EGFR expression level were detection and correlated with the advanced stadium of nasopharyngeal undifferentiated carcinoma. Conclusion: EBNA-1 is significantly related to EGFR expression in the advanced stadium of undifferentiated nasopharyngeal carcinoma. Overexpression of EGFR is mostly found in advanced NPC but not in all ages. Male is dominated and overall age below 55 years old. Screening of EGFR with immunohistochemistry is highly considered before anti-EGFR treatment.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a head and neck malignancy arising from the epithelial cells of the nasopharynx it is rare in most of the world but common in certain geographic distribution with remarkably high disease incidence in southeast Asia and southern China with more over 50.000 new [1, 2] . Nasopharyngeal carcinoma (NPC) is squamous cell carcinoma which usually develops around the ostium of the eustachian tube in the lateral wall of the nasopharynx. While the environmental factors and genetic susceptibility play an important role in NPC pathogenesis. Over the years, many environmental and biological factors including tobacco, consumption of salted fish, Epstein-Barr virus (EBV) infection has implicated in the molecular abnormalities as well as genetic factors which are shown to be associated with the risk of Nasopharyngeal carcinoma [1, 3] . Infecting more 90% of the world population EBV infections is present in all poorly and undifferentiated non-keratinizing NPC [3] . The primary infection can be delayed until late adolescence or adulthood [4] . The incidence of NPC in Indonesia cannot be ascertained precisely, it is because the system of recording and reporting has not been integrated. Several studies conducted in teaching hospitals estimated that the incidence in Indonesia is 6.2/100.000 population or around 12.000 new cases per year [5] .
Several studies reported that about 92% of NPC are undifferentiated type. Epstein-Barr virus infection plays an important role in this type. Epstein Barr virus primary infection through the mucosal epithelium of the oropharynx then enters the cell cycle and releases new virion infections. EBNA-1 is a multifunctional protein that plays a role in the process of replication and the control of the episome during cell division in the latent phase. EBNA-1 is expressed in almost all malignancies associated with Epstein-Barr virus infection thus EBNA-1 is thought to have an important function as a regulator of protein expression and viral DNA replication [6, 7] .
Epidermal growth factor receptor (EGFR) is a 170 kD transmembrane glycoprotein receptor with intrinsic tyrosine kinase activity regulating cell growth, including cell survival, differentiation, motility, and cell proliferation. The role of EGFR is carried out through intracellular signal transduction which causes cell proliferation that affecting tumor development [8] . Increased EGFR expression was found in more than 80% of patients and this was associated with regional lymph node metastasis, recurrence, and poor survival. Increased EGFR expression is associated with poor therapeutic outcomes that affect five-year survival. So that EGFR is thought to be the only prognosis factor that independently predicts recurrence and loco-regional failure that can cause death. In the study, Huang (2010) also found that EGFR which was expressed had a higher recurrence rate than unexpressed EGFR (p=0.015). Unexpressed EGFR has a 5-year survival and free survival which is much better overall compared to EGFR expressed (p=0.015; 0.013) [9] . Therefore, EGFR is an important factor that regulates the development and progression of nasopharyngeal carcinoma. However, the role and mechanism of EGFR in NPC has not been fully understood [10, 11] . Hence this study was conducted to investigate how the relation between EBNA-1 expression and EGFR at an advanced stage of undifferentiated nasopharyngeal carcinoma. Overexpression of the EGFR is a hallmark of SCCHN (squamous cell carcinoma head and neck). High expression of EGFR occurs in the most epithelial malignancies including SCCHN. Overexpression or mutation of EGFR is found 80-100% of the patients with SCCHN, and both are associated with poor prognosis and decreased survival [12] . Monoclonal Antibodies (mAbs) against EGFR are currently used for therapy of recurrent or metastatic diseases; however, their mode of action is not completely understood. In the present, EFGR is considered as a primary target anti tumors strategies [13, 14] .
MATERIAL AND METHODS
This study was approved by the Health Research Ethics Committee of Dr. Soetomo Hospital. This study was an analytical observational study with a crosssectional design. Conducted at sub-department of oncology ENT clinic. Nasopharyngeal biopsy and nasopharyngeal carcinoma type examination were held in Anatomical Pathology laboratory Dr. Moewardi General Hospital Surakarta, Anatomical Pathology laboratory Medical Faculty of Sebelas Maret University and Kalbe genomic for staining and interpreting of EBNA-1 and EGFR expressions using immunohistochemistry staining examination techniques.
The biopsies samples were a new undifferentiated patient with the advanced stadium of nasopharyngeal carcinoma based on AJCC/UICC. The study was conducted from March 2018 until the sample size was fulfilled until August 2018. There were 34 study samples divided with inclusion and exclusion criteria. The Inclusion criterion was the overexpression EGFR. EBNA-1 expression was examined by using Mouse Monoclonal (IgG1) to Epstein-Barr Virus EBV EBNA-1 R and calculated by immunohistochemistry using an "Allred" score [15] . (table 1), EGFR expression was examined using Rabbit Polyclonal to Human EGFR and calculated, immunohistochemistry used immunohistochemistry examination scores (table 2) [16] . 
RESULT
The biopsies number of 34 samples from paraffin blocks embedded were performed with hematoxylin eosin (HE) with undifferentiated nasopharyngeal carcinoma before immunohistochemistry examination. In this study, it was showed that the mean age of patients with advanced stage of undifferentiated nasopharyngeal carcinoma was 55.67 years old with the youngest age of 42 y.o and the oldest age of 77 y.o. The research subject who had the youngest age was 42 years, and the oldest was 77 years old. In this study, NPC was predominant in male (82.35%). All samples underwent hematoxylin eosin staining, revealing undifferentiated carcinoma of nasopharyngeal cancer (100%) before continuing with immunohistochemistry procedure, four samples had been excluding with negative staining. The majority of the study subjects had the expression of EBNA-1 of 70%, while EBNA-1 which was not expressed was 30%. Meanwhile, the measurement of EFGR variables for all study subjects was found that most of the study subjects had strong expression of EFGR (+3) which was 66.67%. Most of the other research subjects had moderate expression EFGR (+2) which was 23.33%, and the rest were research subjects with a weak expressed EFGR (+1) which was 10% of all the subjects in the advanced stage of undifferentiated nasopharyngeal carcinoma. EBNA-1 expression founding negative on stage III is 20%, stage IV by 10%, whereas EBNA-1 positive expression on stage III is 20% and at stage IV by 50%. There is a relationship among EBNA-1 expression and an advanced stage of undifferentiated nasopharyngeal carcinoma with a statistical value of; p=0.048; r=0.372 (p<0.05). Table 6 . The relation of EGFR expression and advanced stage of undifferentiated nasopharyngeal carcinoma connection.
The relation between EGFR expression and advanced stage of undifferentiated nasopharyngeal carcinoma
Low expression of EGFR (+1) in stage III by 6.66% and at stage IV by 3.34%. EGFR was moderately expressed (+2) in stage III by 16.67% and in stage IV by 6.66%; whereas EGFR was strongly expressed (+3) in stage III by 16 .67% and at stage IV by 50%. There is a connection among EGFR expression with advanced stage undifferentiated nasopharyngeal carcinoma with a statistical value of; p=0.021; r=0.421 (p<0.05). In stage III of undifferentiated nasopharyngeal carcinoma (12 patients) had low expression of EGFR (+1) in negative, EBNA-1 expression 8.33%, positive EBNA-1 expression was 8.33%. The Moderate EGFR expression (+2) was in negative EBNA-1 expression (41.67%) and strong EGFR expression (+3) on EBNA-1 expression positive 41.67%. There was a relation between EBNA-1 expression and EGFR in stage III undifferentiated nasopharyngeal carcinoma with statistical value of p=0.022; r=0.652 (p <0.05). The undifferentiated nasopharyngeal carcinoma on stage IV, 18 patients with low EGFR (+1) in negative EBNA-1 expression are 5.56%. Moderate expression of EGFR (+2) in negative EBNA-1 expression is 11.11%, and strong expression of EGFR (+3) in EBNA-1 positive expression was 83.33%. The correlation between the expression of EBNA-1 and EGFR on stage IV undifferentiated nasopharyngeal carcinoma obtained statistical value of; p= 0.00; r=0.996 (p<0.05). The general result, there is a connection among EBNA-1 and EGFR expression in the advanced stage IV of undifferentiated nasopharyngeal carcinoma with a statistical value of p=0.000; r=0.774 (p<0.05).
The relation between EBNA-1 and EGFR expression in the advanced stage of undifferentiated nasopharyngeal carcinoma

DISCUSSION
The findings are consistent with previous epidemiological studies, Adham et.al. which reported that the distribution of nasopharyngeal carcinoma patients was more dominant in men, with a male: female ratio of 70.4%:29.6%, while the highest average age was in the 41-50 year with a percentage of 32.4%, the youngest age <21 years was equal to 9.9% and the oldest age >70 years was 1.9% [17] . Other studies which were conducted in various countries outside Indonesia found similar results, Mak conducted a cohort study on 558 patients with nasopharyngeal carcinoma obtained a ratio of male: female by 73.3%: 26.7%, with an average age of the patients, was 51.8 years with the youngest age of 14 years and the oldest age of 94 years [18] . Another study showed a comparison of male: female nasopharyngeal carcinoma patients by 82.6%:17.4%, with a median age of the research subject was 50 years. Chen from his study of 530 nasopharyngeal carcinoma patients, obtained a ratio of male:female by 74.34%:25.66%, with an average age of the research subject was 44 years, with the youngest age was 16 years, and the oldest age was 79 years [19] .
Thus it can be said that most of the patients with an advanced stage of undifferentiated nasopharyngeal carcinoma are men. This is probably due to carcinogenic substances exposure such as cigarette smoke, alcohol consumption, and other carcinogenic substances. Based on the age of the patient, an advanced stage of undifferentiated nasopharyngeal carcinoma is more often in adulthood, this is due to being a carcinoma requires time to develop into an advanced stage.
In this study expressed EBNA-1 was found at 70% from the advanced stadium, while unexpressed EBNA-1 was found at 30%. This is in line with previous studies, Lao, 2017 conducted a study on 31 nasopharyngeal carcinomas biopsied tissue, EBNA-1 expression was calculated using the same technique (immunohistochemistry) obtaining 77.42% expressed EBNA-1, whereas in healthy nasopharyngeal tissue were not EBNA-1 expression. Borthakur obtained the results of EBNA-1 expression in nasopharyngeal carcinoma by 92.5%. Xiao et al., conducted a study of the expression of EBNA-1 in all types of nasopharyngeal carcinoma and obtained 79.5% EBNA-1 expression [11] .
EBNA-1 expression was associated with an advanced stage of undifferentiated nasopharyngeal carcinoma (p=0.048; r=0.372 (p<0.05). This shows that EBNA-1 is a protein expressed in all latent phases due to Epstein-Barr virus infection. EBNA-1 as a multifunctional protein that relates to the process of replication and control of the episome during cell division. EBNA-1 has a variety of strain which is the specific, stable and long half-life of the translation process to mRNA. The role of EBNA-1 primarily increases TGF-β regulation which resulting in an increase in cell proliferation in undifferentiated nasopharyngeal carcinoma. EBNA-1 activity is carried out by activating the Akt pathway (through β-catenin upregulation), ERK (through upregulation of NFκ-B, AP-1) to increase cell proliferation. EBNA-1 also acts as an E-Cadherin up regulator, so that the tumor can invade. EBNA-1 can initiate the transition of nasopharyngeal carcinoma epithelial cells and promote nasopharyngeal carcinoma cells to migrate and to invade surrounding cells. Noh (2016) in his study proved the inhibition of ERK could cause suppression of EBNA-1 function, this finding proved the role of EBNA-1 in the activation of the EBNA-1 signaling pathway through upregulation of the ERK pathway [20] . Wang obtained 87.5% EBNA-1 expression in nasopharyngeal carcinoma biopsy tissue, and EBNA-1 expression was related to tumor stage (p=0.000), pathological stage (p=0.018) in undifferentiated type, and EBNA expression -1 is associated with regional lymph node metastasis (p=0.003). This is also in line with this study, found an association between EBNA-1 expression was associated with the clinical stage (clinical stage/T) (p=0.00; r=0.769) regional neck lymph node enlargement (p=0.000; r=0.749) [20] .
The expression of EBNA-1 in NPC tissue resembles the role of Epstein-Barr virus infection in patients with nasopharyngeal carcinoma. In this study, not all patients with advanced stage of undifferentiated nasopharyngeal carcinoma expressed EBNA-1, several factors may contribute to this finding, such as undifferentiated nasopharyngeal carcinoma include the type of examination used the specificity and sensitivity of the reagents, equipment as well as the method of calculating the results [21] . EFGR in this study was strongly expressed (+3) which is equal to 66.67% and EFGR (+1) expression was 10%, and no negative EGFR expression was found. Previous studies, Liu (2015) obtained an expressed EGFR of 89.5% and it was associated with tumor expansion and the presence of regional neck lymph node enlargement, Yang reported 89.5% of EGFR expression, and its association with the spread around the tumor (T) and regional lymph node enlargement (N) [22] . EGFR expression plays an important role in nasopharyngeal carcinoma; thus it is often referred to as an independent factor in the development of nasopharyngeal carcinoma [8] .
In the normal epithelium, there is a balance of cellular differentiation and well-controlled cellular proliferation. In epithelial malignancies as in nasopharyngeal carcinoma, uncontrolled growth is mediated by EGFR. Increased EGFR expression in tumor cells will cause tumors to develop, a process of tumor invasion by 60 percent and EGFR expression associated with poor clinical outcomes. Resulting in increased cell proliferation and regional lymph node metastases [23, 24] .
Increased EGFR expression causes activation of the PKC pathway (with increasing STAT3), PI3K pathway (with increasing Cyclin E) leading to increased cell proliferation. Zhang in his study reported that EGFR expression related to the clinical stage of tumor T (p=0.005) and that EGFR expression associated with advanced stages (p=0.001). Pan (2013) mentions EGFR plays a role in STAT3 upregulation, in which increased STAT3 will increase the expression of cyclin-D1 and cMyc which then regulates the G1 phase in the cell cycle so that the cell cycle continuously progresses and the tumor develops [25] . STAT3 also enhances the formation of regional lymph node enlargement. This is in accordance with this study, it was found an association between EGFR expression with clinical stage (clinical stage/T) (clinical stage/T) (p=0.000; r=0.860) and associated regional lymph node metastases (p=0.000; r=0.795).
Immunohistochemistry (IHC) protocols use monoclonal antibodies of EGFR on paraffin specimens sliced on a microtome. The main indication of IHC is a definition on histogenesis, differential diagnosis between reactive and neoplastic states, etiologic diagnosis of infectious disease, determination of prognosis factor, determination of target therapy sites, the location of primary tumors in malignant disease, determination of specific products (such as hormones and protein and cancer subtyping) [26] . IHC has played a significant role in primary tumor site identification in metastatic disease. Panels labeling Squamous cell carcinoma, adenocarcinoma, thyroid carcinoma, sarcoma, lymphoma, neuroendocrine carcinoma, and melanoma can improve diagnostic accuracy and thus provide valuable input to the determination of the most effective course of therapy. The technique helps in screening head and neck tumors, mainly in diagnosing sarcomas and lymphomas and enabling their adequate classification [26] . Immunohistochemistry has significantly improved the outlook for pathology test. The study have shown overexpression of EGFR only in the advanced stage but not in the early stage of NPC from IHC score.
The author cannot find subjects with the advanced stage of undifferentiated nasopharyngeal carcinoma had EGFR expression. This may be in the form of errors in sample collection, techniques for examining EGFR expression, interpretation of the results of immunohistochemistry examinations (semi-quantitative examination techniques are very dependent on the examiner's ability) so that they can influence the expression results. EBNA-1 is a multifunctional protein which plays a role in the process of replication and control of the episome during cell division in the latent phase. EBNA-1 is expressed in almost all malignancies associated with Epstein-Barr virus infection so that EBNA-1 has an important function as a regulator of protein expression and viral DNA replication. EGFR, which is a receptor on the cell membrane, is a growth factor receptor that regulates basic cell behavior including cell survival, differentiation, motility, and proliferation. EBNA-1 influence EGFR expression at an advanced stage of undifferentiated nasopharyngeal carcinoma. Overexpression of EGFR is potential for targeted therapy with the anti-EGFR antibody. IHC showed that immunohistochemical staining for specific EGFR antibodies are a reliable source for diagnostic of mutation and confirming previous reports [27] . The recent study proposed of EGFR to be used as a predictor and prognostic factor for a new generation in NPC therapy with anti-EGFR.
CONCLUSION
The findings are consistent with previous epidemiological studies, Adham et.al,. which reported that the distribution of nasopharyngeal carcinoma patients was more dominant in men, with male:female ratio of 70.4%:29.6%, while the highest average age was in the 41-50 year with a percentage of 32.4%, the youngest age <21 years was equal to 9.9% and the oldest age >70 years was 1.9% [5] . Other studies which were conducted in various countries outside Indonesia found similar results, Mak conducted a cohort study on 558 patients with nasopharyngeal carcinoma obtained a ratio of male: female by 73.3%:26.7%, with an average age of the patients, was 51.8 years with the youngest age of 14 years and the oldest age of 94 years [18] . Another study showed a comparison of male: female nasopharyngeal carcinoma patients by 82.6%: 17.4%, with a median age of the research subject was 50 years. Chen from his study of 530 nasopharyngeal carcinoma patients, obtained a ratio of male:female by 74.34%:25.66%, with an average age of the research subject was 44 years, with the youngest age was 16 years, and the oldest age was 79 years [19] .
EBNA-1 expression was associated with an advanced stage of undifferentiated nasopharyngeal carcinoma (p=0.048; r=0.372 (p<0.05). This shows that EBNA-1 is a protein expressed in all latent phases due to Epstein-Barr virus infection. EBNA-1 as a multifunctional protein that relates to the process of replication and control of the episome during cell division. EBNA-1 has a variety of strain which is the specific, stable and long half-life of the translation process to mRNA. The role of EBNA-1 primarily increases TGF-β regulation which resulting in an increase in cell proliferation in undifferentiated nasopharyngeal carcinoma.EBNA-1 activity is carried out by activating the Akt pathway (through β-catenin upregulation), ERK (through upregulation of NFκ-B, AP-1) to increase cell proliferation. EBNA-1 also acts as an E-Cadherin up regulator, so that the tumor can invade. EBNA-1 can initiate the transition of nasopharyngeal carcinoma epithelial cells and promote nasopharyngeal carcinoma cells to migrate and to invade surrounding cells. Noh (2016) in his study proved the inhibition of ERK could cause suppression of EBNA-1 function, this finding proved the role of EBNA-1 in the activation of the EBNA-1 signaling pathway through upregulation of the ERK pathway [20] . Wang obtained 87.5% EBNA-1 expression in nasopharyngeal carcinoma biopsy tissue, and EBNA-1 expression was related to tumor stage (p=0.000), pathological stage (p=0.018) in undifferentiated type, and EBNA expression -1 is associated with regional lymph node metastasis (p=0.003). This is also in line with this study, found an association between EBNA-1 expression was associated with the clinical stage (clinical stage/T) (p=0.00; r=0.769) regional neck lymph node enlargement (p=0.000; r=0.749) [6] .
The expression of EBNA-1 in NPC tissue resembles the role of Epstein-Barr virus infection in patients with nasopharyngeal carcinoma. In this study, not all patients with advanced stage of undifferentiated nasopharyngeal carcinoma expressed EBNA-1, several factors may contribute to this finding, such as undifferentiated nasopharyngeal carcinoma include the type of examination used the specificity and sensitivity of the reagents, equipment as well as the method of calculating the results [21] .
EFGR in this study was strongly expressed (+3) which is equal to 66.67% and EFGR (+1) expression was 10%, and no negative EGFR expression was found. Previous studies, Liu (2015) obtained an expressed EGFR of 89.5% and it was associated with tumor expansion and the presence of regional neck lymph node enlargement, Yang reported 89.5% of EGFR expression, and its association with the spread around the tumor (T) and regional lymph node enlargement (N) [22] . EGFR expression plays an important role in nasopharyngeal carcinoma; thus it is often referred to as an independent factor in the development of nasopharyngeal carcinoma [8] .
Immunohistochemistry (IHC) protocols use monoclonal antibodies of EGFR on paraffin specimens sliced on a microtome. The main indication of IHC is a definition on histogenesis, differential diagnosis between reactive and neoplastic states, etiologic diagnosis of infectious disease, determination of prognosis factor, determination of target therapy sites, the location of primary tumors in malignant disease, determination of specific products (such as hormones and protein and cancer subtyping) [26] . IHC has played a significant role in primary tumor site identification in metastatic disease. Panels labeling Squamous cell carcinoma, adenocarcinoma, thyroid carcinoma, sarcoma, lymphoma, neuroendocrine carcinoma, and melanoma can improve diagnostic accuracy and thus provide valuable input to the determination of the most effective course of therapy. The technique helps in screening head and neck tumors, mainly in diagnosing sarcomas and lymphomas and enabling their adequate classification [26] . Immunohistochemistry has significantly improved the outlook for pathology test. This study have shown overexpression of EGFR only in the advanced stage but not in the early stage of NPC from IHC score.
The author did not find subjects with the advanced stage of undifferentiated nasopharyngeal carcinoma had EGFR expression. This may be in the form of errors in sample collection, techniques for examining EGFR expression, interpretation of the results of immunohistochemistry examinations (semi-quantitative examination techniques are very dependent on the examiner's ability) so that they can influence the expression results. EBNA-1 is a multifunctional protein which plays a role in the process of replication and control of the episome during cell division in the latent phase. EBNA-1 is expressed in almost all malignancies associated with Epstein-Barr virus infection so that EBNA-1 has an important function as a regulator of protein expression and viral DNA replication. EGFR, which is a receptor on the cell membrane, is a growth factor receptor that regulates basic cell behavior including cell survival, differentiation, motility, and proliferation. EBNA-1 influence EGFR expression at an advanced stage of undifferentiated nasopharyngeal carcinoma. Overexpression of EGFR is potential for targeted therapy with the anti-EGFR antibody. IHC showed that immunohistochemical staining for specific EGFR antibodies are a reliable source for diagnostic of mutation and confirming previous reports. The recent study proposed of EGFR to be used as a predictor and prognostic factor for a new generation in NPC therapy with anti-EGFR.
